drugset
drugset / Trial / NCT02160353

Neo-adjuvant Abiraterone Prostate Study

NCT02160353 ↗

Phase 2 Completed 45 enrolled Cancer Trials Ireland Janssen, LP · collab
NaSingle-groupOpen-labelTreatment

Summary

The role of this study is to focus on the potential role of abiraterone acetate in treatment-naive patients newly diagnosed with high-risk localised prostate cancer requiring combined hormonal therapy and radiotherapy.

Timeline

Start
2015-07-09
Primary completion
2021-01-19
Completion
2021-01-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Abiraterone acetate Small molecule 1000 mg Oral
Subject Prednisolone Other / unclassified 5 mg Oral

Indications

No indication recorded.